{
    "sponsor_name": "",
    "study_acronym": "",
    "tested_imp": "",
    "comparative_drug": "",
    "study_type": "",
    "interventional_study_phase": "",
    "study_design": "",
    "aim_of_study": "",
    "target_disease": "",
    "type_of_randomization": "",
    "randomization_stratification": [],
    "apixaban_dosing": "",
    "dalteparin_dosing": "",
    "apixaban_supply_form": "",
    "dalteparin_supply_form": "",
    "scheduled_visits": [],
    "primary_efficacy_outcome": "Incidence of objectively confirmed recurrent Venous Thromboembolism (VTE), a composite endpoint comprising proximal Deep Vein Thrombosis (DVT) of the lower limbs (symptomatic or unsuspected), symptomatic DVT of the upper limb, and Pulmonary Embolism (PE) (symptomatic or unsuspected).",
    "secondary_efficacy_outcomes": [
        "Individual components of the primary efficacy outcome",
        "Symptomatic recurrence of VTE",
        "All-cause death",
        "Major cardiovascular events",
        "All venous thromboembolic events"
    ],
    "primary_safety_outcome": "",
    "secondary_safety_outcomes": [],
    "maximum_sample_size_per_arm": 0,
    "recommended_inclusion_criteria": [],
    "recommended_exclusion_criteria": []
}